UK markets open in 1 hour 26 minutes
NIKKEI 225
38,667.05 -188.32 (-0.48%) HANG SENG
18,539.07 -282.09 (-1.50%) CRUDE OIL
80.14 +0.31 (+0.39%) GOLD FUTURES
2,358.90 +2.40 (+0.10%) DOW
38,852.86 -216.74 (-0.55%) Bitcoin GBP
53,825.42 +673.72 (+1.27%)
Oramed Pharmaceuticals Inc. (ORMP)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 89.38M |
| Enterprise value | -54.65M |
| Trailing P/E | 9.00 |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 142.16 |
| Price/book (mrq) | 0.57 |
| Enterprise value/revenue | -25.49 |
| Enterprise value/EBITDA | 1.70 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.86 |
| 52-week change 3 | -45.54% |
| S&P500 52-week change 3 | 26.94% |
| 52-week high 3 | 4.3600 |
| 52-week low 3 | 1.6700 |
| 50-day moving average 3 | 2.5082 |
| 200-day moving average 3 | 2.5547 |
Share statistics
| Avg vol (3-month) 3 | 111.89k |
| Avg vol (10-day) 3 | 107.43k |
| Shares outstanding 5 | 40.63M |
| Implied shares outstanding 6 | 40.63M |
| Float 8 | 36.8M |
| % held by insiders 1 | 11.27% |
| % held by institutions 1 | 14.05% |
| Shares short (15 May 2024) 4 | 304.6k |
| Short ratio (15 May 2024) 4 | 3.36 |
| Short % of float (15 May 2024) 4 | 0.83% |
| Short % of shares outstanding (15 May 2024) 4 | 0.75% |
| Shares short (prior month 15 Apr 2024) 4 | 367.6k |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:12 |
| Last split date 3 | 23 Jan 2013 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 1,551.33% |
| Operating margin (ttm) | -2,006.38% |
Management effectiveness
| Return on assets (ttm) | -4.65% |
| Return on equity (ttm) | 6.48% |
Income statement
| Revenue (ttm) | 674k |
| Revenue per share (ttm) | 0.02 |
| Quarterly revenue growth (yoy) | N/A |
| Gross profit (ttm) | N/A |
| EBITDA | -13.31M |
| Net income avi to common (ttm) | 10.46M |
| Diluted EPS (ttm) | 0.2400 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 176.59M |
| Total cash per share (mrq) | 4.35 |
| Total debt (mrq) | 32.56M |
| Total debt/equity (mrq) | 19.65% |
| Current ratio (mrq) | 5.28 |
| Book value per share (mrq) | 4.11 |
Cash flow statement
| Operating cash flow (ttm) | -6.22M |
| Levered free cash flow (ttm) | -7.14M |
© 2024 Yahoo. All rights reserved.